



HEALTHCARE

## **THE CANCER MARKET OUTLOOK TO 2009**

By Steven Seget

 [Table of Contents](#)

## **Steven Seget**

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and graduated from the London School of Economics in Accounting & Finance. [sseget@delphipharma.com](mailto:sseget@delphipharma.com)

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the business development and licensing functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. [www.delphipharma.com](http://www.delphipharma.com)

Copyright © 2004 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Cancer Market Outlook to 2009

<b>Executive Summary</b>	<b>12</b>	
<b>Patient potential</b>	<b>12</b>	
<b>Global market analysis</b>	<b>13</b>	
<b>Leading players in the cancer market</b>	<b>14</b>	
<b>Development of key cancer markets to 2009</b>	<b>15</b>	
<b>Chapter 1</b>	<b>Patient potential</b>	<b>18</b>
<b>Summary</b>		<b>18</b>
<b>Introduction</b>		<b>19</b>
<b>Lung cancer</b>		<b>20</b>
Disease description		20
Epidemiology		21
Current treatments		22
NSCLC		22
SCLC		22
Malignant mesothelioma		23
Current therapeutics		23
Unmet needs		23
<b>Breast cancer</b>		<b>24</b>
Disease description		24
Epidemiology		25
Current treatments		26
Current therapeutics		26
Unmet needs		27
<b>Prostate cancer</b>		<b>28</b>
Disease description		28
Epidemiology		29
Current treatments		30
Current therapeutics		31
Unmet needs		31
<b>Colorectal cancer</b>		<b>32</b>
Disease description		32

Epidemiology	32
Current treatments	33
Current therapeutics	34
Unmet needs	34
<b>Ovarian cancer</b>	<b>35</b>
Disease description	35
Epidemiology	35
Current treatments	36
Current therapeutics	37
Unmet needs	37
<b>Leukemia</b>	<b>38</b>
Disease description	38
Epidemiology	38
Current treatments	39
Current therapeutics	40
Unmet needs	40

## **Chapter 2                      Global market analysis                      44**

<b>Summary</b>	<b>44</b>
<b>Introduction</b>	<b>45</b>
Global analysis	45
<b>Hormonal therapies</b>	<b>49</b>
Introduction	49
Market overview	50
LHRH agonists	53
Drug analysis	55
Lupron/Leuplin	55
Zoladex	59
Decapeptyl	61
Anti-androgens	62
Drug analysis	63
Casodex	63
Androcur	67
Anti-estrogens	68
Drug analysis	69
Nolvadex	69
Aromatase inhibitors	73
Drug analysis	74
Arimidex	74
Femara	77
Aromasin	81
Progestagens	83
Drug analysis	84
Depo-Provera	84
Megace	86

<b>Cytotoxics</b>	<b>87</b>
Introduction	87
Market overview	89
‘Other’ cytotoxics	92
Drug analysis	93
Taxotere	93
Taxol	95
Paraplatin	98
Camptosar/Campto	100
Eloxatin	103
Antimetabolites	106
Drug analysis	107
Gemzar	107
UFT	111
Xeloda	113
Furtulon	115
Cytotoxic antibiotics	117
Drug analysis	119
Pharmorubicin/Ellence	119
Doxil/Caelyx	121
Alkylating agents	122
Drug analysis	124
Temodar	124
Ifex/Holoxan	126
Vinka alkaloids and etoposide	126
Drug analysis	127
Navelbine	127
VePesid	128
<b>Innovative cancer therapies</b>	<b>129</b>
Market overview	130
Cytokines	133
Drug analysis	133
Intron franchise	133
Proleukin	136
Monoclonal antibodies	138
Drug analysis	139
MabThera/Rituxan	139
Herceptin	141
‘Other’ innovatives	145
Glivec/Gleevec	145
Iressa	147
Therapeutic vaccines and photodynamic therapy	147
Drug analysis	148
Melacine	148
M-Vax	149
OncoVAX	150
Photofrin	151
Angiogenesis inhibitors	152
Drug analysis	153
<b>Adjunct therapies</b>	<b>154</b>

Market overview	156
Anti-emetics	158
Drug analysis	159
Zofran	159
Kytril	160
Emend	161
Bisphosphonates	162
Drug analysis	163
Zometa	163
Aredia	165
HGFs	166
Drug analysis	166
Procrit/Eporex	166
Epogen and Aranesp	168
Neupogen and Neulasta	172

## **Chapter 3                      Leading players in the cancer market                      177**

<b>Summary</b>	<b>177</b>
<b>Introduction</b>	<b>178</b>
<b>Global breakdown</b>	<b>178</b>
<b>Amgen</b>	<b>180</b>
Marketed products	180
R&D compounds	180
palifermin	182
panitumumab	184
Mobist (Flt3 ligand)	185
Osteoprotegerin - oncology	185
AMG-706	186
Apo2L/TRAIL (PRO 1762)	186
LymphoCide	187
Oncology portfolio sales forecasts and forecast revenue growth	187
<b>AstraZeneca</b>	<b>188</b>
Marketed products	188
R&D compounds	189
ZD-6474	189
ZD-4054	189
ZD-6126	190
AZD-2171	190
Oncology portfolio sales forecasts and forecast revenue growth	190
<b>Aventis</b>	<b>191</b>
Marketed products	191
R&D compounds	191
Dynepo (epoetin delta)	192
Genasense	193

Flavopiridol	193
Oncology portfolio sales forecasts and forecast revenue growth	194
<b>Bristol-Myers Squibb</b>	<b>194</b>
Marketed products	194
R&D compounds	195
Erbix/IMC-C225 (cetuximab)	197
BMS-247550 (epothilone)	197
BMS-184476	198
BMS-214662 (Farnesyl transferase inhibitor)	198
BMS-275291	199
BMS-182751/JM-216 (satraplatin)	199
Combretastatin	200
Cancer portfolio sales forecasts and forecast revenue growth	200
<b>GlaxoSmithKline</b>	<b>201</b>
Marketed products	201
R&D compounds	202
Bexxar (tositumomab)	202
nelarabine (506U78)	202
572016	203
Oncology portfolio sales forecasts and forecast revenue growth	204
<b>Novartis</b>	<b>205</b>
Marketed products	205
R&D compounds	206
ICL670 (deferasirox)	206
PTK787	207
PKC412	209
OctreoTher	209
EPO906	209
SOM230	211
Oncology portfolio sales forecasts and forecast revenue growth	211
<b>Pfizer</b>	<b>212</b>
Marketed products	212
R&D compounds	213
SU11248	213
J-107088 (endotecarin)	216
SU6668	216
CI-1033 (canertinib)	216
AG-013736	217
Oncology portfolio sales forecasts and forecast revenue growth	217
<b>Roche</b>	<b>218</b>
Marketed products	218
R&D compounds	219
Bondronat/Bonviva (ibandronate)	220
Femara (letrozole)	222
Avastin/anti-VEGF	224
Tarceva/R1415/OSI-744	224
R1549 (pemtumomab)	227
Oncology portfolio sales forecasts and forecast revenue growth	229

<b>Chapter 4</b>	<b>Development of key cancer markets to 2009</b>	<b>232</b>
<b>Summary</b>		<b>232</b>
<b>Introduction</b>		<b>233</b>
<b>Global market</b>		<b>233</b>
<b>The hormonal therapy market</b>		<b>235</b>
<b>Cytotoxics</b>		<b>237</b>
<b>Innovative therapies</b>		<b>239</b>
<b>Adjunct therapies</b>		<b>241</b>
<b>Analysis of key novel products</b>		<b>242</b>
Introduction		242
Alimta		242
Avastin		245
Bexxar		247
Erbixar		249
Genasense		253
Iressa		255
Velcade		259
<b>Appendix</b>		<b>264</b>
<b>References</b>		<b>264</b>
<b>Index</b>		<b>265</b>

# List of Figures

Figure 2.1:	The global cancer market, 1999–2003	47
Figure 2.2:	Competitive dynamics of drug classes within the global cancer market, 2003	48
Figure 2.3:	Evolution of the hormonal drug therapy market, 1970–2003	50
Figure 2.4:	Market share of the leading hormonal therapies, 2003	53
Figure 2.5:	Lupron: SWOT analysis	58
Figure 2.6:	Zoladex: SWOT analysis	61
Figure 2.7:	Casodex: SWOT analysis	67
Figure 2.8:	Nolvadex: SWOT analysis	72
Figure 2.9:	Arimidex: SWOT analysis	77
Figure 2.10:	Femara: SWOT analysis	80
Figure 2.11:	Aromasin: SWOT analysis	83
Figure 2.12:	Evolution of the cytotoxic drug therapy market, 1940–2003	88
Figure 2.13:	Market share of the leading cytotoxics, 2003	91
Figure 2.14:	Taxotere: SWOT analysis	95
Figure 2.15:	Taxol: SWOT analysis	97
Figure 2.16:	Paraplatin: SWOT analysis	100
Figure 2.17:	Camptosar/Campto: SWOT analysis	103
Figure 2.18:	Eloxatin: SWOT analysis	105
Figure 2.19:	Gemzar: SWOT analysis	111
Figure 2.20:	UFT: SWOT analysis	113
Figure 2.21:	Xeloda: SWOT analysis	115
Figure 2.22:	Furtulon: SWOT analysis	117
Figure 2.23:	Pharmorubicin/Ellence: SWOT analysis	120
Figure 2.24:	Temodar: SWOT analysis	125
Figure 2.25:	Evolution of the innovative cancer drug market, 1986–2003	130
Figure 2.26:	Market share of the leading innovative cancer drugs, 2003	132
Figure 2.27:	PEG Intron: SWOT analysis	135
Figure 2.28:	Market share of the leading adjunct therapy drugs, 2003	158
Figure 3.29:	Competitive dynamics of key players within the global cancer market, 2003	179
Figure 4.30:	Development of the global cancer market, 2003–09	234

# List of Tables

Table 1.1:	Lung cancer patient statistics across the seven major pharmaceutical markets, 2003	21
Table 1.2:	Breast cancer patient statistics across the seven major pharmaceutical markets, 2003	25
Table 1.3:	Prostate cancer patient statistics across the seven major pharmaceutical markets, 2003	29
Table 1.4:	Colorectal cancer patient statistics across the seven major pharmaceutical markets, 2003	33
Table 1.5:	Ovarian cancer patient statistics across the seven major pharmaceutical markets, 2003	36
Table 1.6:	Leukemia patient statistics across the seven major pharmaceutical markets, 2003	39
Table 2.7:	The global cancer market, 1999–2003	46
Table 2.8:	Expected patent expiry on key hormonal therapies	51
Table 2.9:	Breakdown of the global hormonal therapy market, 2001–03	52
Table 2.10:	Breakdown of the global cytotoxics market, 2001–03	90
Table 2.11:	The innovative cancer drug market, 2001–03	131
Table 2.12:	The adjunct therapy market, 2001–2003	157
Table 3.13:	Key players in the global cancer market, 2002–03	179
Table 3.14:	Amgen’s marketed cancer portfolio, 2004	180
Table 3.15:	Amgen’s cancer R&D pipeline, 2004	182
Table 3.16:	Forecast sales for Amgen’s cancer portfolio (\$m), 2003–09	188
Table 3.17:	AstraZeneca’s marketed cancer portfolio, 2004	188
Table 3.18:	AstraZeneca’s cancer R&D pipeline, 2004	189
Table 3.19:	Forecast sales for AstraZeneca’s cancer portfolio, 2003–09	190
Table 3.20:	Aventis’ marketed cancer portfolio, 2004	191
Table 3.21:	Aventis’ cancer R&D pipeline, 2004	192
Table 3.22:	Forecast sales for Aventis’ cancer portfolio, 2003–09	194
Table 3.23:	BMS’s marketed cancer portfolio, 2004	195
Table 3.24:	BMS’s cancer R&D pipeline, 2004	196
Table 3.25:	Forecast sales for BMS’s cancer portfolio (\$m), 2003–09	200
Table 3.26:	GSK’s marketed cancer portfolio, 2004	201
Table 3.27:	GSK’s cancer R&D pipeline, 2004	202
Table 3.28:	Forecast sales for GSK’s cancer portfolio, 2003–09	205
Table 3.29:	Novartis’ marketed cancer portfolio, 2004	205
Table 3.30:	Novartis’ cancer R&D pipeline, 2004	206
Table 3.31:	Forecast sales for Novartis’ cancer portfolio, 2003–09	211
Table 3.32:	Pfizer’s marketed cancer portfolio, 2004	212
Table 3.33:	Pfizer’s cancer R&D pipeline, 2004	213
Table 3.34:	Forecast sales for Pfizer’s cancer portfolio, 2003–09	217
Table 3.35:	Roche’s marketed cancer portfolio, 2004	218
Table 3.36:	Roche’s cancer R&D pipeline, 2004	220
Table 3.37:	Forecast sales for Roche’s cancer portfolio, 2003–09	230
Table 4.38:	Development of the global cancer market, 2003–09	234
Table 4.39:	Sales breakdown for the hormonal therapies market, 2003–09	235
Table 4.40:	Sales breakdown for the cytotoxic therapies market, 2003–09	237
Table 4.41:	Sales breakdown for the innovative therapies market, 2003–09	239
Table 4.42:	Sales breakdown for the adjunct therapies market, 2003–09	241